The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | Key therapeutic markers in gastroesophageal cancers: HER2, PDL1, MSI & more
Ronan Kelly, MD, Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas, TX comments on the therapeutic landscape surrounding gastroesophageal cancers. He highlights four therapeutic targets that are currently of mainstream focus: HER2, PDL1, microsatellite instability (MSI), and CLDN18.2, and notes evidence targeting CDK4/6 is primarily in a investigator-initiated Phase I/II trial (NCT04921904). This interview took place at the 2025 American Society of Clinical Oncology (ASCO) meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
